Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma

Journal of Cutaneous Pathology

Volumn 35, Issue 10, 2008, Pages 916-921

  Janisson Dargaud, Delphine ^a   Durlach, Anne ^b   Lorenzato, Marianne ^b   Grange, Florent ^a   Bernard, Philippe ^a   Birembaut, Philippe ^b  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔPITAL MAISON BLANCHE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BASAL CELL CARCINOMA; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROTEIN EXPRESSION;

AGED; ANEUPLOIDY; CARCINOMA, BASAL CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 51649086999     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2007.00935.x     Document Type: Article

References (31)

1. Rubin A, Chen E, Ratner D. Basal cell carcinoma. N Engl J Med 2005 353 : 2262.
2. Miller SJ. Biology of basal cell carcinoma (Part 1). J Am Acad Dermatol 1991 24 : 1.
3. Rowe DE, Carroll R, Day CL. Long term recurrence rate in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989 15 : 315.
4. Coulomb A. ANAES. Recommendations for basal carcinoma. Ann Dermatol Venereol 2004 131 : 661 756.
5. Robinson JK, Fisher SG. Recurrent basal cell carcinoma after incomplete resection. Arch Dermatol 2000 136 : 1318.
6. Barrett TL, Smith KJ, Hodge JJ, Butler R, Hall FW, Skelton HG. Immunohistochemical nuclear staining for p53, PCNA, and Ki 67 in different histologic variants of basal cell carcinoma. J Am Acad Dermatol 1997 37 : 430.
7. Bolshakov S, Walker C, Strom S, et al. p53 mutations in human aggressive and non aggressive basal and squamous cell carcinomas. Clin Cancer Res 2003 9 : 228.
8. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001 37 Suppl. 4 S9.
9. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ. Prognostic significance of EGFR and Her 2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer 2003 89 : 681.
10. Lavrijsen AP, Tieben LM, Ponec M, van der Schroeff JG, van Muijen GN. Expression of EGF receptor, involucrin, and cytokeratins in basal cell carcinomas and squamous cell carcinomas of the skin. Arch Dermatol Res 1989 281 : 83.
11. Kikushi A, Amagai M, Hayakawa K, et al. Association of EGF receptor expression with proliferating cells and of ras p21 expression with differentiating cells in various skin tumors. Br J Dermatol 1990 123 : 49.
12. Hagedorn M, Vansscheidt W, Strasser W, Bauknecht T. Determination of epidermal growth factor (EGF) receptors in basal cell carcinomas, squamous cell carcinomas and melanomas. Z Hautkr 1990 65 : 568.
13. Yerebakan O, Ciftcioglu MA, Akkaya BK, Yilmaz E. Prognostic value of Ki 67, CD 31 and epidermal growth factor receptor expression in basal cell carcinoma. J Dermatol 2003 30 : 33.
14. Healy E, Angus B, Lawrence CM, Rees JL. Prognostic value of Ki 67 antigen expression in basal cell carcinomas. Br J Dermatol 1995 133 : 737.
15. Ewers SB, Attewell R, Baldetrop B, Borg A, Langstrom E, Killander D. Prognostic potential of flow cytometric S-phase and ploïdy prospectively determinated in primary breast carcinomas. Breast Cancer Res Treat 1991 20 : 93.
16. Stephenson RA, James BC, Gay H, Fair WH, Whitmore WF, Melamed PR. Flow cytometry of prostate cancer: relationship of DNA content to survival. Cancer Res 1987 47 : 2504.
17. Kallioniemi OP, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy and S-phase fraction in ovarian cancer. Cancer 1988 61 : 334.
18. Brinck U, Korabiowska M, Knapik J, et al. Comparison of the DNA content in recurrent and nonrecurrent basaliomas of the face. Pol J Pathol 1998 49 : 97.
19. Lorenzato M, Lallemand A, Visseaux-Coletto B, Gaillard D. Quantification de l'ADN par analyse d'image sur coupes en paraffine. Ann Pathol 1994 14 : 257.
20. Lanza G, Gafa R, Santini A, et al. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer 1998 1 : 49.
21. Staibano S, Lo Muzio L, Pannone G, et al. DNA ploidy and cyclin D1 expression in basal cell carcinoma of the head and neck. Am J Clin Pathol 2001 115 : 805.
22. Pierga JY, Leroyer A, Vielh P, Mosseri V, Chevillard S, Magdelénat H. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 1996 37 : 57.
23. Popov Z, Hoznek A, Colombel M, et al. The prognostic value of p53 nuclear overexpression and MIB 1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997 80 : 1472.
24. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003 284 : 99.
25. F Penault-Lorca, Durando X, Bay JO. Prognostic value of epidermal growth factor. Bull Cancer 2003 90 : S192.
26. Li S, Kim JS, Kim JM, et al. EGFR as a prognostic actor in locally advanced rectal cancer treated with preoperative chemo radiation. Int J Radiat Oncol Biol Phys 2006 65 : 705.
27. Bauknecht T, Gross G, Hageborn M. Epidermal growth factor receptors in different skin tumors. Dermatologica 1985 171 : 16.
28. Nazmi Mn, Dykes PJ, Marks R. Epidermal growth factor in human epidermal tumours. Br J Dermatol 1990 123 : 153.
29. Ro YS. Oncogene interaction in basal cell carcinomas of human skin. J Ko Med Sc 1995 10 : 85.
30. Krähn G, Leiter U, Kaskel P, et al. Coexpression pattern of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001 37 : 251.
31. Banerjee D, Guindi AK, Haliotis MM, et al. Best practice standards for EGFR testing in colorectal cancer in Canada. SNELL Medical Communication 2005. published by Snell, 2005.